卖什么
Our drugs engage the immune system to fight tumors
商业模式拆解
买家：谁掌握预算？
未核实Prospective pharma licensing partners and investors.
工作流：什么输入变成什么输出？
Block a cancer immune-evasion pathway with a first-in-class, orally administered small-molecule inhibitor that does not rely on a protein target, re-awakening the immune system.
经济账：省了什么，怎么收费？
未核实Preclinical/early drug developer; revenue model not stated, likely licensing or partnering.
渠道：怎么接触到客户？
Contact via info@erisbio.com; no commercial channel yet.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2024 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.